)

Quince Therapeutics (QNCX) investor relations material
Quince Therapeutics Investor Day 2025 summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Technology and Platform Overview
Developed a proprietary autologous intracellular drug encapsulation (AID) platform using a mobile, automated machine to load drugs into a patient's own red blood cells for reinfusion, enabling chronic delivery of corticosteroids while minimizing toxicity.
Lead program is encapsulated dexamethasone sodium phosphate (EDSP/eDSP), designed for monthly dosing to maintain therapeutic levels and avoid toxic plasma concentrations associated with conventional steroids.
Over 425 participants have received at least one dose of EDSP/eDSP, with more than 7,800 infusions administered, supporting a strong safety and efficacy profile.
The technology is CE marked in Europe, has undergone rigorous regulatory review, and is protected by a robust patent portfolio and proprietary device components.
20+ years of R&D and $100 million investment in AIDE technology underpin the platform.
Clinical Development and Data
Pivotal Phase III NEAT trial in ataxia telangiectasia (A-T) has completed enrollment, focusing on children aged 6–9, with top-line results expected in Q1 2026.
Previous ATTEST Phase III trial showed a 24% difference versus placebo in the target age group, with no major safety concerns and strong efficacy signals in posture and gait endpoints.
RNA sequencing from the ATTEST trial revealed that EDSP/eDSP downregulates interferon-stimulated and pro-inflammatory genes, reduces inflammation, and upregulates neuroprotective and mitochondrial genes, supporting a disease-modifying mechanism.
NEAT trial conducted under FDA Special Protocol Assessment, with high data integrity and compliance, and primary endpoint focused on clinically meaningful outcomes.
A pediatric study required by the EMA will enroll 12 children aged 2–6 to assess PK and safety, using wearable devices to explore new functional endpoints.
Regulatory and Commercial Strategy
Orphan drug and Fast Track designations granted in the US and EU, providing market exclusivity (7 years US, 10 years EU) and regulatory advantages.
NDA submission for eDSP in A-T planned for the second half of 2026, with a request for Priority Review and the US following a 505(b)(2) pathway leveraging existing dexamethasone data.
Commercial launch preparations include a partnership with Option Care Health, enabling broad US infusion center coverage and streamlined patient access.
Market opportunity for A-T estimated at $1B+ in the US alone, with potential to expand as awareness and diagnosis increase.
Strong patent protection until at least 2036, with additional technology barriers to generic competition.
Next Quince Therapeutics earnings date

Next Quince Therapeutics earnings date

The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
)
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
)
I can't remember the last time an app had such a positive impact on my investment process.
)
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
)
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
I can't remember the last time an app had such a positive impact on my investment process.
)
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
)
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
)
)
)
Frequently asked questions
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Explore our global coverage